Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Summary

This phase II trial is studying cetuximab to see how well it works in treating patients with persistent or recurrent cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Timeline

Start

2007-06

Primary completion

2012-01

Completion

—

Drugs

Indications